Spyre Therapeutics Inc

SYRE has broken decisively below its 9-, 20-day EMAs and 50-day SMA, shifting into a corrective/distribution phase. Short-term momentum remains negative, with price extended below declining EMAs and oversold RSI triggering temporary relief risk but no sustained stabilization. Medium-term bias is firmly bearish, favoring execution on rallies into the dynamic resistance zone around the 97–100 EMA area. Sell Now is recommended to capture further downside with rejection at EMAs.

• ↑Multiple analysts maintain Buy ratings with $120–$140 targets
• ↑Launched SPY772 Phase 2 SKYLIGHT trial targeting Hidradenitis Suppurativa
• ↓Weak profitability factors highlight margin and return challenges